摘要
目的:概述现有调血脂药(他汀类、贝特类、烟酸类、胆汁酸螯合剂及调血脂新药微粒体三酰甘油转运蛋白抑制剂洛美他派)对家族性高胆固醇血症的临床疗效和安全性。方法:检索近10年国内外相关文献和临床治疗指南。结果与结论:临床上常用调脂药物单药治疗因其疗效不足或安全性问题已不能满足家族性高胆固醇血症患者的需求,而洛美他派显示出较好的临床疗效和耐受性。
OBJECTIVE To review the clinical efficacy and safety of lipid-modifying drugs（such as statins, fibrates, niacin, bile acid chelating resins and microsomal triglyceride transfer protein inhibitors-lomitapide） in the treatment of familial hyper eholesterolaemia. METHODS The domestic and oversea pertinent literatures since 2000 and the clinical treatment guidelines were researched. RESULTS and CONCLUSION Generic lipid-modifying drugs used as monotherapy have not already been used to meet the needs of patients with familial hypercholesterolaemia because of inadequate efficacy and safety. Lomitapide can be an effective adjuvant for patients with familial hypercholesterolaemia.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2014年第5期415-419,共5页
Chinese Journal of Hospital Pharmacy
